Publication Date
7-1-2023
Journal
PLoS Biology
DOI
10.1371/journal.pbio.3002112
PMID
37467291
PMCID
PMC10355383
PubMedCentral® Posted Date
7-19-2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
Mice, Animals, Blood-Brain Barrier, Capsid, Genetic Vectors, Central Nervous System, Capsid Proteins, Dependovirus
Abstract
Viruses have evolved the ability to bind and enter cells through interactions with a wide variety of cell macromolecules. We engineered peptide-modified adeno-associated virus (AAV) capsids that transduce the brain through the introduction of de novo interactions with 2 proteins expressed on the mouse blood-brain barrier (BBB), LY6A or LY6C1. The in vivo tropisms of these capsids are predictable as they are dependent on the cell- and strain-specific expression of their target protein. This approach generated hundreds of capsids with dramatically enhanced central nervous system (CNS) tropisms within a single round of screening in vitro and secondary validation in vivo thereby reducing the use of animals in comparison to conventional multi-round in vivo selections. The reproducible and quantitative data derived via this method enabled both saturation mutagenesis and machine learning (ML)-guided exploration of the capsid sequence space. Notably, during our validation process, we determined that nearly all published AAV capsids that were selected for their ability to cross the BBB in mice leverage either the LY6A or LY6C1 protein, which are not present in primates. This work demonstrates that AAV capsids can be directly targeted to specific proteins to generate potent gene delivery vectors with known mechanisms of action and predictable tropisms.
Included in
Biochemistry, Biophysics, and Structural Biology Commons, Biology Commons, Integrative Medicine Commons, Neurology Commons, Neurosciences Commons
Comments
Associated Data